Infliximab Dosing Schedule for Ankylosing Spondylitis
For ankylosing spondylitis, infliximab should be administered at 5 mg/kg intravenously at weeks 0,2, and 6, followed by maintenance dosing every 6-8 weeks. This is the FDA-approved regimen and is supported by the highest quality evidence 1.
Standard Dosing Regimen
The established protocol consists of:
- Induction phase: 5 mg/kg IV at weeks 0,2, and 6
- Maintenance phase: 5 mg/kg IV every 6-8 weeks thereafter 1, 2
This dosing schedule has demonstrated robust efficacy, with approximately 60% of patients achieving ASAS20 response by week 24, with clinical benefit observable as early as week 2 3. The response is maintained with continued regular infusions 4.
Dose and Interval Adjustments
If patients have inadequate response or lose response over time, the dose can be increased up to 10 mg/kg or the interval shortened to as frequently as every 4 weeks 1, 2. However, be aware that higher doses carry increased risk of serious infections 1.
Real-world evidence suggests that dose and interval modifications are common and can improve clinical outcomes. In one Korean study, approximately 54% of patients had treatment pattern changes (dose or interval adjustments), and these patients showed greater improvements in disease activity scores compared to those without modifications 5. Drug survival was not negatively impacted by these adjustments 5.
Important Clinical Considerations
Patients who do not respond by week 14 are unlikely to respond with continued dosing and should have treatment discontinued 1. This is a critical decision point to avoid unnecessary exposure to a costly medication with potential adverse effects.
Monitoring Requirements
Before initiating and periodically during therapy 1:
- Tuberculosis screening (PPD or interferon gamma release assay) is mandatory
- Baseline: CBC, liver function tests, hepatitis profile
- Ongoing: Periodic history and physical examination, consider yearly PPD, periodic CBC and LFTs
Infusion Administration
- Infusions should be given over 2-3 hours 6
- Premedication with antihistamines, acetaminophen, and/or corticosteroids may be considered to reduce infusion reactions 1
- Approximately 20% of patients experience infusion reactions 1
- Have appropriate personnel and medications available to treat anaphylaxis
Combination Therapy Considerations
Concomitant methotrexate is not required for ankylosing spondylitis (unlike rheumatoid arthritis where it is recommended) 1. However, some clinicians use low-dose methotrexate to reduce antibody formation against infliximab, which can lead to loss of efficacy 6, 7.
Comparative Efficacy
Among TNF inhibitors, indirect comparison suggests that infliximab 5 mg/kg at the standard induction schedule may be the most efficacious therapy for AS 8. Notably, a 3 mg/kg dose showed inferior efficacy and should not be used 8, 9.
Duration of Effect
Withdrawal of long-term therapy typically leads to disease flares within weeks to months, though rare cases of lasting remission have been reported 10. Continuous therapy is generally required to maintain disease control 4.
Contraindications
Infliximab at doses ≥5 mg/kg should not be given to patients with New York Heart Association functional class III or IV congestive heart failure 6.